Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Vijay K. Gunuganti

Oncology
Texas Oncology
Texas Oncology PA
18707 Hardy Oak Blvd, Suite 320, 
San Antonio, TX 
Accepting New Patients
Offers Telehealth

Advanced in WT1-Related Wilms Tumor Syndromes
Texas Oncology
Texas Oncology PA
18707 Hardy Oak Blvd, Suite 320, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vijay Gunuganti is an Oncologist in San Antonio, Texas. Dr. Gunuganti is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Myelodysplastic Syndrome (MDS), Multiple Myeloma, Lung Cancer, and Renal Cell Carcinoma (RCC). Dr. Gunuganti is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Baptist Medical Center
Methodist Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Netcare Life And Health Insurance
  • OTHER COMMERCIAL
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

TEXAS ONCOLOGY PA
18707 Hardy Oak Blvd, Suite 320, San Antonio, TX 78258
Call: 210-545-6972

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


3 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
View 2 Less Clinical Trials

3 Total Publications

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 10, 2020
View All 3 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rebecca E. Barrington
Oncology | Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rebecca E. Barrington
Oncology | Hematology Oncology

Texas Oncology PA

694 Hill Country Dr, 
Kerrville, TX 
 (49.9 miles away)
830-792-3434
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rebecca Barrington is an Oncologist and a Hematologist Oncology provider in Kerrville, Texas. Dr. Barrington is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Paget Disease of the Breast, Large-Cell Immunoblastic Lymphoma, Colorectal Cancer, and Childhood Iron Deficiency Anemia. Dr. Barrington is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Alyssa G. Rieber
Hematology Oncology | Oncology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Alyssa G. Rieber
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

506 W Windcrest St, Suite 300, 
Fredericksburg, TX 
 (51.0 miles away)
830-990-0255
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alyssa Rieber is a Hematologist Oncology specialist and an Oncologist in Fredericksburg, Texas. Dr. Rieber is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Breast Cancer, Paget Disease of the Breast, and Pleuropulmonary Blastoma. Dr. Rieber is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Thomas B. Tucker
Oncology | Hematology Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Thomas B. Tucker
Oncology | Hematology Oncology

Texas Oncology PA

694 Hill Country Dr, 
Kerrville, TX 
 (49.9 miles away)
830-792-3434
Languages Spoken:
English, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Tucker is an Oncologist and a Hematologist Oncology provider in Kerrville, Texas. Dr. Tucker is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Follicular Lymphoma, Familial Colorectal Cancer, Lynch Syndrome, and Colorectal Cancer. Dr. Tucker is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gunuganti's expertise for a condition
ConditionClose
      • Advanced
      • Chromophobe Renal Cell Carcinoma
        Dr. Gunuganti is
        Advanced
        . Learn about Chromophobe Renal Cell Carcinoma.
        See more Chromophobe Renal Cell Carcinoma experts
      • Clear Cell Sarcoma
        Dr. Gunuganti is
        Advanced
        . Learn about Clear Cell Sarcoma.
        See more Clear Cell Sarcoma experts
      • Colorectal Cancer
        Dr. Gunuganti is
        Advanced
        . Learn about Colorectal Cancer.
        See more Colorectal Cancer experts
      • Familial Colorectal Cancer
        Dr. Gunuganti is
        Advanced
        . Learn about Familial Colorectal Cancer.
        See more Familial Colorectal Cancer experts
      • Familial Wilms Tumor 2
        Dr. Gunuganti is
        Advanced
        . Learn about Familial Wilms Tumor 2.
        See more Familial Wilms Tumor 2 experts
      • Lung Cancer
        Dr. Gunuganti is
        Advanced
        . Learn about Lung Cancer.
        See more Lung Cancer experts
      View All 14 Advanced Conditions
      • Experienced
      • Adult Soft Tissue Sarcoma
        Dr. Gunuganti is
        Experienced
        . Learn about Adult Soft Tissue Sarcoma.
        See more Adult Soft Tissue Sarcoma experts
      • Agranulocytosis
        Dr. Gunuganti is
        Experienced
        . Learn about Agranulocytosis.
        See more Agranulocytosis experts
      • ALK-Positive Non-Small Cell Lung Cancer
        Dr. Gunuganti is
        Experienced
        . Learn about ALK-Positive Non-Small Cell Lung Cancer.
        See more ALK-Positive Non-Small Cell Lung Cancer experts
      • Anal Cancer
        Dr. Gunuganti is
        Experienced
        . Learn about Anal Cancer.
        See more Anal Cancer experts
      • Angiosarcoma
        Dr. Gunuganti is
        Experienced
        . Learn about Angiosarcoma.
        See more Angiosarcoma experts
      • Bladder Cancer
        Dr. Gunuganti is
        Experienced
        . Learn about Bladder Cancer.
        See more Bladder Cancer experts
      View All 71 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2025 All Rights Reserved